- Home
- RNAZ vs KYNB Comparison
RNAZ vs KYNB Comparison
Compare RNAZ & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNAZ | KYNB |
|---|---|---|
| Founded | 2016 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 32.8M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RNAZ | KYNB |
|---|---|---|
| Price | $1.77 | $4.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $38.50 |
| AVG Volume (30 Days) | ★ 26.9K | 21.1K |
| Earning Date | 08-14-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9552.08 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $6,440,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.52 | $4.85 |
| 52 Week High | $13.92 | $9.66 |
Technical Indicators
Market Signals| Indicator | RNAZ | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 47.56 | 24.00 |
| Support Level | $1.55 | N/A |
| Resistance Level | $1.93 | $7.41 |
| Average True Range (ATR) | 0.16 | 0.35 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 57.25 | 2.23 |
Price Performance
Historical ComparisonAbout RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.